BEIJING, Nov. 20, 2024 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Highlights
Third Quarter 2024 Operational Highlights
Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, said, "Our third quarter performance beat the high end of our guidance once again, highlighting the resilience of our business. Sales of medical products and maintenance services grew by 18.7% year-over-year, becoming a key growth driver contributing to a year-over-year increase in net income. This underscores the effectiveness of our strategy to stay at the forefront of industry trends by deepening the synergies from our vertical integration and continuously diversifying our offerings. Our clinic network has experienced significant growth. The number of stores has grown to 16 by the end of this quarter, extending our presence into additional major cities. All stores are situated in central business districts, enhancing our market coverage and competitive position. To further scale our offline presence, we are accelerating the deployment of this proven standardized model in other cities nationwide and are exploring franchising opportunities to engage with a wider audience. The reputational strength of our brand and our deep understanding of evolving consumer behavior uniquely position us to develop products that resonate with consumer needs. Sales momentum remains robust, driven by both our well-established products and exciting new launches in collaboration with our supply chain partners. Looking ahead, we are committed to seizing opportunities across the entire medical aesthetics value chain while deepening the integration of our three core businesses to maximize operational efficiency, customer satisfaction, and sustainable growth."
Mr. Hui Zhao, Chief Financial Officer of So-Young, added, "Our third-quarter results reflect our ability to strategically adapt to changing market dynamics. Through disciplined cost management and targeted growth initiatives, we are carefully navigating this challenging market environment while building a solid foundation for future expansion. Encouragingly, our net income and non-GAAP net income attributable to So-Young International Inc. improved significantly, with year-over-year growth rates exceeding 8.9% and 133.1% respectively. Looking ahead, we will leverage our expanding network of clinics and meticulously curated product offerings to address the growing demand for high-quality solutions and services. By maintaining operational efficiency and scalability, we are well-positioned to continue leading the medical aesthetics sector, delivering sustainable growth and long-term value for our shareholders."
[1] This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.0176 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on September 30, 2024. |
[2] Non-GAAP net income attributable to So-Young International Inc. is defined as net income attributable to So-Young International Inc. excluding share-based compensation expenses attributable to So-Young International Inc. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release. |
Third Quarter 2024 Financial Results
Revenues
Total revenues were RMB371.8 million (US$53.0 million), a decrease of 3.5% from RMB385.3 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.
Cost of Revenues
Cost of revenues was RMB142.2 million (US$20.3 million), a decrease of 0.3% from RMB142.6 million in the third quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with the information services. Cost of revenues included share-based compensation expenses of RMB0.1 million (US$0.0 million), compared with the share-based compensation expenses of RMB0.4 million in the corresponding period of 2023.
Operating Expenses
Total operating expenses were RMB225.0 million (US$32.1 million), a decrease of 8.1% from RMB244.7 million in the third quarter of 2023.
Income Tax (Expenses)/Benefits
Income tax expenses were RMB2.1 million (US$0.3 million), compared with income tax benefits of RMB2.2 million in the same period of 2023.
Net Income Attributable to So-Young International Inc.
Net income attributable to So-Young International Inc. was RMB20.3 million (US$2.9 million), compared with a net income attributable to So-Young International Inc. of RMB18.3 million in the third quarter of 2023.
Non-GAAP Net Income Attributable to So-Young International Inc.
Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses attributable to So-Young International Inc., was RMB22.2 million (US$3.2 million), compared with RMB9.5 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2023.
Basic and Diluted Earnings per ADS
Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.20 (US$0.03) and RMB0.20 (US$0.03), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.18 and RMB0.18, respectively, in the same period of 2023.
Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments
As of September 30, 2024, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,252.6 million (US$178.5 million), compared with RMB1,341.6 million as of December 31, 2023.
Business Outlook
For the fourth quarter of 2024, So-Young expects total revenues to be between RMB350.0 million (US$49.9 million) and RMB370.0 million (US$52.7 million), representing a 10.4% to 5.3% decrease from the same period in 2023. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.
Non-GAAP Financial Measures
To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income attributable to So-Young International Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.
Conference Call Information
So-Young's management will hold an earnings conference call on Wednesday, November 20, 2024, at 7:00 AM U.S. Eastern Time (8:00 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:
International: | +1-412-902-4272 |
Mainland China: | 4001-201203 |
US: | +1-888-346-8982 |
Hong Kong: | +852-301-84992 |
Passcode: | So-Young International Inc. |
A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, November 27, 2024. The dial-in details are:
International: | +1-412-317-0088 |
US: | +1-877-344-7529 |
Passcode: | 2642052 |
Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.
About So-Young International Inc.
So-Young International Inc. (Nasdaq: SY) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young's strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.
For more information, please contact:
So-Young
Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Christensen
In China
Ms. Dee Wang
Phone: +86-10-5900-1548
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
SO-YOUNG INTERNATIONAL INC. | |||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
(Amounts in thousands, except for share and per share data) | |||||
As of | |||||
December 31, | September 30, | September 30, | |||
2023 | 2024 | 2024 | |||
RMB | RMB | US$ | |||
Assets | |||||
Current assets: | |||||
Cash and cash equivalents | 426,119 | 467,407 | 66,605 | ||
Restricted cash and term deposits | 14,695 | 104,198 | 14,848 | ||
Trade receivables | 57,219 | 106,943 | 15,239 | ||
Inventories | 118,924 | 145,601 | 20,748 | ||
Receivables from online payment platforms | 23,158 | 31,666 | 4,512 | ||
Amounts due from related parties | 9,212 | 10,466 | 1,491 | ||
Term deposits and short-term investments | 900,823 | 681,035 | 97,047 | ||
Prepayment and other current assets | 171,774 | 221,227 | 31,525 | ||
Total current assets | 1,721,924 | 1,768,543 | 252,015 | ||
Non-current assets: | |||||
Long-term investments | 261,016 | 287,507 | 40,969 | ||
Intangible assets | 145,253 | 131,641 | 18,759 | ||
Goodwill | 540,693 | 540,693 | 77,048 | ||
Property and equipment, net | 116,782 | 154,572 | 22,026 | ||
Deferred tax assets | 78,034 | 81,057 | 11,551 | ||
Operating lease right-of-use assets | 118,408 | 159,179 | 22,683 | ||
Other non-current assets | 232,455 | 180,628 | 25,739 | ||
Total non-current assets | 1,492,641 | 1,535,277 | 218,775 | ||
Total assets | 3,214,565 | 3,303,820 | 470,790 | ||
Liabilities | |||||
Current liabilities: | |||||
Short-term borrowings | 29,825 | 89,559 | 12,762 | ||
Taxes payable | 56,894 | 53,639 | 7,643 | ||
Contract liabilities | 103,374 | 94,747 | 13,501 | ||
Salary and welfare payables | 86,290 | 84,927 | 12,102 | ||
Amounts due to related parties | 388 | 146 | 21 | ||
Accrued expenses and other current liabilities | 233,913 | 244,721 | 34,873 | ||
Operating lease liabilities-current | 29,739 | 40,398 | 5,757 | ||
Total current liabilities | 540,423 | 608,137 | 86,659 | ||
Non-current liabilities: | |||||
Operating lease liabilities-non current | 86,210 | 124,915 | 17,800 | ||
Deferred tax liabilities | 25,082 | 20,780 | 2,961 | ||
Other non-current liabilities | 1,536 | 1,607 | 229 | ||
Total non-current liabilities | 112,828 | 147,302 | 20,990 | ||
Total liabilities | 653,251 | 755,439 | 107,649 | ||
SO-YOUNG INTERNATIONAL INC. | |||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued) | |||||
(Amounts in thousands, except for share and per share data) | |||||
Shareholders' equity: | |||||
Treasury stock | (358,453) | (369,907) | (52,711) | ||
Class A ordinary shares (US$0.0005 par value; 750,000,000 | 238 | 252 | 36 | ||
Class B ordinary shares (US$ 0.0005 par value; 20,000,000 | 37 | 37 | 5 | ||
Additional paid-in capital | 3,080,433 | 3,067,567 | 437,125 | ||
Statutory reserves | 33,855 | 33,855 | 4,824 | ||
Accumulated deficit | (330,166) | (312,117) | (44,476) | ||
Accumulated other comprehensive income | 18,185 | 8,858 | 1,262 | ||
Total So-Young International Inc. shareholders' equity | 2,444,129 | 2,428,545 | 346,065 | ||
Non-controlling interests | 117,185 | 119,836 | 17,076 | ||
Total shareholders' equity | 2,561,314 | 2,548,381 | 363,141 | ||
Total liabilities and shareholders' equity | 3,214,565 | 3,303,820 | 470,790 |
SO-YOUNG INTERNATIONAL INC. | ||||||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
(Amounts in thousands, except for share and per share data) | ||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||
September | September | September | September | September | September | |||||||
RMB | RMB | US$ | RMB | RMB | US$ | |||||||
Revenues: | ||||||||||||
Information services and others | 285,937 | 262,988 | 37,475 | 795,100 | 750,952 | 107,010 | ||||||
Reservation services | 24,140 | 19,567 | 2,788 | 80,724 | 64,987 | 9,261 | ||||||
Sales of medical products and maintenance services | 75,217 | 89,270 | 12,721 | 231,639 | 281,548 | 40,120 | ||||||
Total revenues | 385,294 | 371,825 | 52,984 | 1,107,463 | 1,097,487 | 156,391 | ||||||
Cost of revenues: | ||||||||||||
Cost of services and others | (103,484) | (98,620) | (14,053) | (291,503) | (274,695) | (39,144) | ||||||
Cost of medical products sold and maintenance services | (39,119) | (43,548) | (6,206) | (115,199) | (139,839) | (19,927) | ||||||
Total cost of revenues | (142,603) | (142,168) | (20,259) | (406,702) | (414,534) | (59,071) | ||||||
Gross profit | 242,691 | 229,657 | 32,725 | 700,761 | 682,953 | 97,320 | ||||||
Operating expenses: | ||||||||||||
Sales and marketing expenses | (143,844) | (114,884) | (16,371) | (394,276) | (360,448) | (51,363) | ||||||
General and administrative expenses | (50,242) | (69,901) | (9,961) | (204,097) | (225,653) | (32,155) | ||||||
Research and development expenses | (50,597) | (40,188) | (5,727) | (158,531) | (122,277) | (17,424) | ||||||
Total operating expenses | (244,683) | (224,973) | (32,059) | (756,904) | (708,378) | (100,942) | ||||||
(Loss)/Income from operations | (1,992) | 4,684 | 666 | (56,143) | (25,425) | (3,622) | ||||||
Other income/(expenses): | ||||||||||||
Investment income, net | 647 | 510 | 73 | 10,869 | 3,397 | 484 | ||||||
Interest income, net | 12,130 | 14,239 | 2,029 | 38,023 | 38,270 | 5,453 | ||||||
Exchange gains/(losses) | 103 | 465 | 66 | (1,051) | 875 | 125 | ||||||
Share of losses of equity method investee | (3,822) | (3,873) | (552) | (10,692) | (11,602) | (1,653) | ||||||
Others, net | 9,887 | 6,915 | 985 | 18,474 | 12,234 | 1,743 | ||||||
Income/(Loss) before tax | 16,953 | 22,940 | 3,267 | (520) | 17,749 | 2,530 | ||||||
Income tax benefits/(expenses) | 2,191 | (2,097) | (299) | 7,240 | 3,031 | 432 | ||||||
Net income | 19,144 | 20,843 | 2,968 | 6,720 | 20,780 | 2,962 | ||||||
Net income attributable to noncontrolling interests | (839) | (495) | (71) | (2,941) | (2,731) | (389) | ||||||
Net income attributable to So-Young International Inc. | 18,305 | 20,348 | 2,897 | 3,779 | 18,049 | 2,573 |
SO-YOUNG INTERNATIONAL INC. | ||||||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued) | ||||||||||||
(Amounts in thousands, except for share and per share data) | ||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||
September | September | September | September | September | September | |||||||
RMB | RMB | US$ | RMB | RMB | US$ | |||||||
Net earnings per ordinary share | ||||||||||||
Net earnings per ordinary share attributable to ordinary shareholder - basic | 0.24 | 0.26 | 0.04 | 0.05 | 0.23 | 0.03 | ||||||
Net earnings per ordinary share attributable to ordinary shareholder - diluted | 0.24 | 0.26 | 0.04 | 0.05 | 0.23 | 0.03 | ||||||
Net earnings per ADS attributable to ordinary shareholders - basic (13 ADS | 0.18 | 0.20 | 0.03 | 0.04 | 0.18 | 0.03 | ||||||
Net earnings per ADS attributable to ordinary shareholders - diluted (13 ADS | 0.18 | 0.20 | 0.03 | 0.04 | 0.18 | 0.03 | ||||||
Weighted average number of ordinary shares used in computing earnings/(loss) | 76,842,709 | 79,493,819 | 79,493,819 | 78,001,149 | 79,544,066 | 79,544,066 | ||||||
Weighted average number of ordinary shares used in computing earnings/(loss) | 77,210,781 | 79,708,518 | 79,708,518 | 78,402,636 | 79,810,666 | 79,810,666 | ||||||
Share-based compensation expenses included in: | ||||||||||||
Cost of services and others | (418) | (81) | (12) | (1,635) | (255) | (36) | ||||||
Sales and marketing expenses | (533) | (183) | (26) | (2,850) | (420) | (60) | ||||||
General and administrative expenses | 11,164 | (1,328) | (189) | (10,400) | (27,796) | (3,961) | ||||||
Research and development expenses | (1,454) | (309) | (44) | (3,636) | (1,969) | (281) | ||||||
* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted. |
SO-YOUNG INTERNATIONAL INC. | ||||||||||||
Reconciliation of GAAP and Non-GAAP Results | ||||||||||||
(Amounts in thousands, except for share and per share data) | ||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||
September | September | September | September | September | September | |||||||
RMB | RMB | US$ | RMB | RMB | US$ | |||||||
GAAP (loss)/income from operations | (1,992) | 4,684 | 666 | (56,143) | (25,425) | (3,622) | ||||||
Add back: Share-based compensation expenses | (8,759) | 1,901 | 271 | 18,521 | 30,440 | 4,338 | ||||||
Non-GAAP (loss)/income from operations | (10,751) | 6,585 | 937 | (37,622) | 5,015 | 716 | ||||||
GAAP net income attributable to So-Young International Inc. | 18,305 | 20,348 | 2,897 | 3,779 | 18,049 | 2,573 | ||||||
Add back: Share-based compensation expenses | (8,759) | 1,901 | 271 | 18,521 | 30,440 | 4,338 | ||||||
Non-GAAP net income attributable to So-Young International Inc. | 9,546 | 22,249 | 3,168 | 22,300 | 48,489 | 6,911 |
Last Trade: | US$0.78 |
Daily Change: | 0.01 1.31 |
Daily Volume: | 28,872 |
Market Cap: | US$67.100M |
August 23, 2024 December 01, 2023 November 20, 2023 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB